A 24-WEEK, PHASE 2B, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GSK1278863 IN SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE WHO ARE NOT ON DIALYSIS
- Registry ID
- PHI113747
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Start date
- 2014-06-26
- Last update
- 2013-09-17
Conditions
Related clinical trials
- PODOMOUNT-BASKET, A PHASE II, MULTICENTRE, RANDOMISED, 2-ARM PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED BASKET TRIAL TO ASSESS SAFETY, TOLERABILITY, PK, AND EFFICACY OF BI 764198 IN FOUR PROTEINURIC KIDNEY DISEASES
- A PHASE 2A, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF VX-407 IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE WHO HAVE A SUBSET OF PKD1 GENE VARIANTS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST
COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON
APPROVED C5-INHIBITOR THERAPY
- A PHASE 2, RANDOMIZED, OPEN-LABEL, STUDY OF MOMELOTINIB IN PARTICIPANTS WITH
ANEMIA DUE TO LOW-RISK MYELODYSPLASTIC SYNDROME
- BLEEDING REDUCTION IN ACUTE AND CHRONIC KIDNEY PATIENTS HAVING SURGERY
(BRACKETS) PILOT TRIAL
- A PHASE IIB, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF BALCINRENONE IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND ALBUMINURIA
View on source registry